A new scientific focus on extrachromosomal circular DNA (eccDNA) is opening transformative possibilities for disease detection, monitoring, and personalized medicine. Once considered a biological curiosity, eccDNA is now emerging as a powerful biomarker with the potential to reshape how a wide range of diseases are identified and managed.

Unlike traditional DNA found within chromosomes, eccDNA exists as stable, circular molecules that operate independently within cells. This unique structure gives eccDNA a significant advantage in clinical applications. Its high stability allows it to persist in challenging biological environments, while its distinct molecular signatures enable precise identification of disease-related changes.

Across multiple disease areas, eccDNA is proving to be highly informative. In cancer, it plays a critical role in shaping tumor behavior by influencing genetic variability, tumor evolution, and treatment response. Its presence in both tissues and bodily fluids creates new opportunities for non-invasive diagnostics, including liquid biopsy, where disease signals can be detected through a simple blood sample.

Beyond detection, eccDNA offers valuable insight into how diseases progress. Its dynamic nature allows it to reflect changes in disease state over time, making it a promising tool for real-time monitoring and treatment evaluation. In particular, its involvement in drug resistance highlights its potential to guide more effective therapeutic strategies by identifying when and how treatments may lose effectiveness.

The impact of eccDNA extends well beyond oncology. In prenatal health, eccDNA circulating in maternal blood provides a window into fetal development, offering safer approaches for identifying conditions such as preeclampsia and growth restriction. In immune-related disorders, eccDNA acts as a potent regulator of immune activity, linking it to conditions such as autoimmune diseases and chronic inflammation.

Its relevance also spans other complex conditions, including metabolic diseases, neurological disorders, and age-related changes, where eccDNA patterns reflect underlying biological processes. This broad applicability positions eccDNA as a versatile and highly informative molecular signal across diverse areas of medicine.

Technological advances are accelerating progress in this field. Modern sequencing approaches now allow for more accurate detection and analysis of eccDNA, revealing its diversity, origins, and functional roles with increasing precision. These innovations are helping to unlock the full potential of eccDNA as a clinically actionable tool.

As understanding continues to grow, eccDNA stands at the forefront of next-generation diagnostics, offering a powerful combination of sensitivity, specificity, and clinical versatility. Its ability to provide early, accurate, and dynamic insights into disease marks a significant step toward more precise and personalized healthcare.

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4 |Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Xuanmei Luo, Jian Cui, Hexin Li, Gang Zhao, Lihui Zou, The potential clinical implications of extrachromosomal circular DNA as a biomarker, Genes & Diseases, Volume 13, Issue 3, 2026, 101734, https://doi.org/10.1016/j.gendis.2025.101734

Funding
National High Level Hospital Clinical Research Funding (China) BJ-2024-095
National High Level Hospital Clinical Research Funding (China) BJ-2023-077